Etofibrate
Top View
- Technology Road Mapping for Innovation Pathways of Fibrates: a Cross-Database Patent Review
- Etofibrate but Not Controlled-Release Niacin Decreases LDL Cholesterol and Lipoprotein (A) in Type Iib Dyslipidemic Subjects
- (12) United States Patent (10) Patent No.: US 6,365,186 B1 Huval Et Al
- Accessibility Improving Information Using Online Patient Drug Reviews
- Bioactive Compound Library Plus (96-Well)
- Changes Highlighted Final Version Date of Issue
- Comparative Study on the in Vivo and in Vitro Antilipolytic Effects of Etofibrate, Nicotinic Acid and Clofibrate in the Rat
- Fenofibrate: a Novel Formulation (Triglide™) in the Treatment of Lipid Disorders: a Review
- Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark∗
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Anatomical Classification Guidelines V2006A EPHMRA ANATOMICAL
- The Role of Fibrates in Primary Biliary Cholangitis
- Trends in Lipid-Modifying Agent Use in 83 Countries
- Pharmaceutical Appendix to the Tariff Schedule 2
- PPARS - Peroxisome Proliferator Activated Receptor Activators and Fibrates Actions Sidney Carvalho Fernandes1, Anita L
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- General Pharmacology and Toxicology”
- Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases